Priyanka Kriplani – författare

Cancer is a leading cause of death worldwide, and the efficacy of cancer drugs is often limited due to poor bioavailability and drug resistance. Traditional treatment strategies, such as surgery, chemotherapy, radiotherapy, immunotherapy, and combinational regimens, are associated with side effects and fail to deliver an adequate amount of the drug to the target site. Chemotherapy has paved the way for novel drug delivery systems in cancer treatment, enhancing efficacy, patient compliance and reducing side effects by specifically targeting the site of action. These novel drug delivery systems employ various drug delivery systems such as nanoparticles, liposomes, niosomes, transferosomes, transdermal drug delivery systems, intranasal drug delivery systems, and others to improve drug solubility, stability, and controlled release patterns. The application of novel drug delivery systems in chemoimmunotherapy has become a hotspot in cancer treatment, and this book explores the potential of gene therapy alongside recent patents on anticancer formulations. The discussion also extends to clinical trials, which are crucial for validating these novel approaches and ensuring that effective treatments reach patients. The initial chapters provide an overview of current therapeutic approaches, while subsequent chapters focus on the role of nanotechnology in cancer treatment, emphasizing various nanoparticle-based formulations. Liposomes, transdermal drug delivery systems, microsomes, phytosomes, niosomes, intranasal drug delivery systems, and gene-drug delivery systems for cancer therapy are also discussed. Furthermore, the book addresses novel drug delivery systems, patents, and ongoing clinical trials, offering valuable insights for researchers, academicians, and scientists working towards advancements in the therapeutic management of cancer.